Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Sheeba Irshad, Carl Graham et al.|The Lancet Oncology|2021Cited by 614
IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast CancersPierfrancesco Marra, Andrew Tutt, Sumi Mathew et al.|Cancer Research|2014Cited by 61
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesLeticia Monin, Sheeba Irshad, Adam G. Laing et al.|medRxiv|2021Cited by 61
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinomaDhruva Biswas, Carlos Martínez‐Ruiz, Yun-Hsin Liu et al.|Nature Cancer|2025Cited by 15